Copyright
©The Author(s) 2023.
World J Cardiol. Jan 26, 2023; 15(1): 13-22
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.13
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.13
STEMI (n = 95) | NSTEMI (n = 38) | USA (n = 33) | P value | |
Risk factors | ||||
Age, yr (mean ± SD) | 61.2 ± 10.1 | 60.2 ± 11.0 | 60.5 ± 10.5 | 0.5 |
Males | 73 (76.8) | 25 (65.8) | 25 (75.8) | 0.5 |
Diabetes | 49 (52) | 20 (52.6) | 14 (42.4) | 0.5 |
Hypertension | 61 (64) | 22 (58) | 21 (64) | 0.8 |
Smoking | 31 (32.6) | 12 (31.6) | 10 (30.3) | 0.9 |
Prior history of CAD | 2 (2.2) | 6 (16.2) | 9 (27.3) | 0.001 |
Clinical features on presentation | ||||
Rest angina | 89 (93.6) | 36 (94.7) | 26 (78.8) | 0.013 |
Ejection fraction < 30% | 42 (44.2) | 10 (26.3) | 5 (15.2) | 0.005 |
Significant ischemic MR | 30 (31.6) | 9 (23.7) | 2 (6.1) | 0.014 |
Killip class ≥ 2 | 24 (25.3) | 7 (18.4) | 2 (6) | 0.057 |
SCAI stage C | 11 (11.6) | 7 (18.4) | 0 | 0.04 |
SCAI stage D | 3 (3.2) | 0 | 0 | 0.3 |
SCAI stage E | 5 (5.3) | 0 | 0 | 0.14 |
Key investigations | ||||
Creatinine, mg/dL (mean ± SD) | 1.17 ± 0.6 | 1.2 ± 0.6 | 1.05 ± 0.47 | 0.42 |
CK-MB, (mean ± SD) | 112 ± 98 | 71 ± 57 | 25 ± 24 | 0.001 |
Fibrinogen, gm/L (mean ± SD) | 6.3 ± 1.2 | 5.3 ± 1.1 | 5.3 ± 1.3 | 0.001 |
Albumin, gm/dL (mean ± SD) | 3.3 ± 0.33 | 3.4 ± 0.36 | 3.5 ± 30 | 0.075 |
FAR (mean ± SD) | 19.1 ± 4.8 | 15.4 ± 4.0 | 15.1 ± 4.3 | 0.001 |
Patients with TIMI- ≤ 1 flow (n = 54) | Patients with TIMI- ≥ 2 flow (n = 98) | P value | |
Age, yr | 60.5 ± 10.2 | 60.5 ± 10.7 | 0.9 |
Time of presentation to hospital after chest pain onset (h) | 13.4 ± 11.2 | 12.3 ± 8.8 | 0.24 |
Hypertension | 33 (61) | 71 (65) | 0.3 |
Active smokers | 16 (29.6) | 36 (32.4) | 0.3 |
EF < 30% | 23 (42.6) | 33 (29.7) | 0.1 |
Cardiogenic shock | 10 (18.5) | 15 (13.5) | 0.4 |
Complete heart block | 8 (14.8) | 7 (6.3) | 0.07 |
Time to initiation of medical treatment, h | 77.3 ± 63 | 74.5 ± 66 | 0.87 |
Time to angiography, h | 107 ± 79 | 113 ± 141 | 0.84 |
CK-MB | 101.2 ± 90 | 75 ± 83.4 | 0.11 |
Platelet (× 109/L) | 1.89 ± 0.7 | 2.0 ± 0.91 | 0.17 |
Procalcitonin (ng/mL) | 0.59 ± 0.7 | 1.0 ± 2.6 | 0.27 |
TLC (× 109/L) | 10.6 ± 3.8 | 10.7 ± 3.9 | 0.8 |
CRP (mg/dL) | 47.2 ± 34.3 | 39.7 ± 28.4 | 0.16 |
Fibrinogen (gm/L) | 6.9 ± 1.04 | 5.4 ± 1.2 | 0.001 |
Albumin (gm/dL) | 3.3 ± 0.35 | 3.4 ± 0.32 | 0.014 |
FAR | 21.1 ± 3.9 | 15.6 ± 4.1 | 0.001 |
- Citation: Makkar K, Sharma YP, Batta A, Hatwal J, Panda PK. Role of fibrinogen, albumin and fibrinogen to albumin ratio in determining angiographic severity and outcomes in acute coronary syndrome. World J Cardiol 2023; 15(1): 13-22
- URL: https://www.wjgnet.com/1949-8462/full/v15/i1/13.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i1.13